TauRx Chairman Claude Wischik On Waging A Battle Against Alzheimer’s His Way: An Interview With PharmAsia News (Part 1 of 2)
This article was originally published in PharmAsia News
Executive Summary
Claude Wischik has spent more than a decade working on a drug that would inhibit the aggregation of tau tangles in the brain, and says his work has put the Singapore-based company TauRx Pharmaceuticals Ltd. onto a path that could produce the world’s best-selling drug, surpassing Pfizer Inc.’s Lipitor (atorvastatin).
You may also be interested in...
Lilly Expands Bet on Tau By Buying Siemens’ Alzheimer’s Imaging Portfolio
The acquisition of a tau PET imaging portfolio from Siemens further expands Lilly’s Alzheimer’s program.
Merck Inks Deal For Second Alzheimer’s Test, This Time With Luminex
Luminex will develop a companion diagnostic for Merck’s BACE Inhibitor, MK-8931, that will test patients’ cerebrospinal fluid for the presence of two biomarkers that could indicate they are at risk of developing Alzheimer’s disease.
Efficacy Signal For Lilly’s Solanezumab Stirs The Alzheimer’s Pot
With the potential for a multi-billion-dollar blockbuster on its hands, Eli Lilly could conduct a confirmatory trial or even seek near-term approval of sola after pooled data revealed a hint of disease modifying potential in mildly affected Alzheimer’s patients, though the company also may be grasping at straws.